MENU
+Compare
IPHA
Stock ticker: NASDAQ
AS OF
Dec 3, 04:59 PM (EDT)
Price
$1.89
Change
-$0.06 (-3.08%)
Capitalization
186.92M

IPHA Innate Pharma SA Forecast, Technical & Fundamental Analysis

Innate Pharma SA is a clinical-stage biotechnology company... Show more

IPHA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for IPHA with price predictions
Nov 28, 2025

IPHA's RSI Indicator ascending out of oversold territory

The RSI Oscillator for IPHA moved out of oversold territory on November 10, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In of the 26 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 28, 2025. You may want to consider a long position or call options on IPHA as a result. In of 109 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IPHA just turned positive on November 26, 2025. Looking at past instances where IPHA's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IPHA advanced for three days, in of 222 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 112 cases where IPHA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

IPHA moved below its 50-day moving average on November 12, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IPHA crossed bearishly below the 50-day moving average on November 06, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for IPHA moved below the 200-day moving average on November 06, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPHA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IPHA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (29.326) is normal, around the industry mean (27.312). P/E Ratio (0.000) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (22.936) is also within normal values, averaging (321.020).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
IPHA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

IPHA is expected to report earnings to fall 52.60% to -14 cents per share on March 19

Innate Pharma SA IPHA Stock Earnings Reports
Q4'25
Est.
$-0.14
Q4'24
Beat
by $0.10
Q2'23
Beat
by $0.16
The last earnings report on March 27 showed earnings per share of -30 cents, beating the estimate of -40 cents. With 15.51K shares outstanding, the current market capitalization sits at 186.92M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
117, Avenue de Luminy
Phone
+33 430303030
Employees
211
Web
https://www.innate-pharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
USSJF8.17N/A
N/A
USS Co. Ltd.
FANUY17.10N/A
N/A
Fanuc Corporation
KMNCF0.39N/A
N/A
Kingsmen Creatives Ltd.
CRPHY2.30N/A
N/A
Ceres Power Holdings plc
BHLIF0.02N/A
N/A
Bradda Head Lithium Limited

IPHA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IPHA has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IPHA jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IPHA
1D Price
Change %
IPHA100%
+2.63%
MDGL - IPHA
43%
Loosely correlated
-1.10%
APLM - IPHA
36%
Loosely correlated
-0.79%
SLNO - IPHA
34%
Loosely correlated
-1.86%
VALN - IPHA
30%
Poorly correlated
-1.57%
TNXP - IPHA
30%
Poorly correlated
+1.91%
More